Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions.
Skip to main content

China

WHO sets dates for reviews of Sinopharm and Sinovac COVID-19 vaccines

1 minute read

A booth displaying a coronavirus vaccine candidate from Sinovac Biotech Ltd is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, China September 4, 2020. REUTERS/Tingshu Wang

GENEVA, April 22 (Reuters) - Technical experts at the World Health Organization (WHO) will review on April 26 Chinese drugmaker Sinopharm's COVID-19 vaccine for possible emergency use listing, to be followed by the Sinovac (SVA.O) jab on May 3, the agency said on Thursday.

"We would expect a decision a couple of days later," the WHO said in response to a Reuters query.

So far COVID-19 vaccines made by Pfizer (PFE.N) AstraZeneca (AZN.L) and Johnson & Johnson (JNJ.N) have received a WHO listing - an endorsement of their safety and efficacy that helps to guide countries' regulatory agencies.

Reporting by Stephanie Nebehay Editing by David Goodman

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters